CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The decrease was primarily due to the recognition of previously received milestone ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on ARVN stock, giving a Buy rating on October 22. Tyler Van Buren’s ...

aDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands bDepartment of Medical Oncology, Erasmus University Medical Centre, Rotterdam, Netherlands ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

Sales of Novartis' CDK4/6 inhibitor Kisqali (ribociclib) were $787 million in Q3 2024, up 40 percent from Q3 2023. The agent, ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines ... If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy.” The ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...